DePuy’s parent company, Johnson & Johnson, has announced that it will enter into a $2.475 billion DePuy hip settlement agreement with plaintiffs in MDL 2197. The DePuy hip settlement covers patients who have undergone a revision surgery as of August 31, 2013. Individuals who have not undergone a revision as of August 31, 2013, still have legal rights available to them and should contact our firm to discuss them.
Various media sources recently announced that an experimental antidote for Pradaxa – an anticoagulant implicated in bleeding deaths – has successfully reversed the effects of the drug in healthy subjects during early trials. One might expect that Pradaxa’s manufacturer, Boehringer-Ingelheim, would be jumping for joy – but the jury is still out. A remedy for serious uncontrolled bleeding brought on by Pradaxa is still sorely needed.
PENSACOLA, FL, OCT.
Most people understand the dangers of an overdose – but you have to know what you are ingesting each time you take a medication. This is particularly true of medications containing acetaminophen, the active ingredient in Tylenol.
The media recently marked a grim milestone. The number of plaintiffs who have filed a vaginal mesh lawsuit has passed the thirty thousand mark. Approximately one third of these are scheduled to be heard in the U.S. District Court, Southern District of West Virginia. Vaginal mesh lawsuit cases currently involve six (6) separate Multidistrict Litigation dockets pertaining to six manufacturers: American Medical Systems, Boston Scientific, Coloplast, Ethicon, Cook Medical and C.R. Bard.
In a ruling released yesterday, a federal appellate court reinterpreted the BP settlement agreement for Business Economic Loss claims related to the Oil Spill in the Gulf. While the appeals court disagreed with the lower court's support for the class administrator's calculation method of business losses according to cash-basis method of accounting, it will now be up to the trial court to further delineate the ruling.
Attorney Brian Barr leads Phase 2 trial on BP’s oil spill in the Gulf
Ring of Fire Radio recently presented a report that may as well be regular feature on the program, these days (perhaps called “Deadly Drug of the Week”). This week, the featured product is protamine sulfate, and is manufactured and sold by our old friends at Fresenius, the fine folks who brought you the dialysis drug Granuflo.
As lawsuits pile up against Fresenius N.A., the pharmaceutical company that manufactures the dialysis drug GranuFlo – implicated in the deaths of hundreds of patients – it's worth taking a look at exactly what is allegedly killing them.
According to the U.S. Food and Drug Administration (FDA), one culprit is metabolic alkalosis.
As corporations race to gobble each other up in an endless quest to become bigger and richer and more profitable and ultimately, more powerful, they often forget that with mergers and acquisitions comes more liability. As the parent company takes on more subsidiaries, it becomes difficult to control quality – and behavior. And, like the parent of a minor child who causes someone an injury or damages property, the parent company likewise ends up being held responsible.
This one has apparently been flying under the radar for awhile.
Recently, we posted a story of how some individuals have been using Tylenol as a method of suicide. The irony here is that according to a study that was done at the University of British Columbia this past spring, the active ingredient in Tylenol – acetaminophen may help people in dealing with “existential dread,” or the overwhelming fear of one's mortality and feelings of uncertainty.
German pharmaceutical giant Boehringer-Ingelheim (BI) is trumpeting the news across the world: their flagship product, Pradaxa (dabigatran), approved in 100 countries around the world for stroke prevention and other life-threatening heart conditions, has netted the company $807 billion in sales in just the first six months of 2013!
If a family member is a patient at a treatment center and the staff administers a medication that causes severe injury or death, who is liable? The facility that purchased the medication? The staff member who administered it? Or perhaps, the company that manufactured it in the first place?
The information about the connection between acetaminophen – the primary ingredient in Tylenol as well as a host of other over-the-counter remedies – and potentially fatal liver damage has not only spawned litigation (eighty cases and counting as of this writing). In accordance with the Law of Unintended Consequences, news about the effects of these inexpensive, easily obtained medications has apparently shown people – especially young teens suffering from depression – a quick but not so easy way out of this life.
$4 Million settlement resolves a civil case arising from jailhouse torture and death.
The news only gets worse for Johnson & Johnson, manufacturer of the popular over-the-counter medication Tylenol. Not only can acetaminophen (the active ingredient in Tylenol) cause serious liver damage, it has been implicated in serious, and even fatal dermal reactions. According to a warning issued by the U.S. Food & Drug Administration at the beginning of August, acetaminophen may result in one of two forms of toxic epidermal necrosis (TEN), a condition in which the outer layer of the skin (epidermis) separates from the lower layer (dermis) due to cell death.
An Escambia County jury rendered a $2.6 Million verdict today in favor of the Estate of Nathaniel McCants, 7 years after McCants’ April 2007 on the job burn injury and death. Lawyers Virginia Buchanan and Cameron Stephenson of the Levin Papantonio firm brought claims on behalf of the Estate against McCants’ job supervisor, Roy Johns, under a rarely used exception to the workers compensation law.
The U.S. Food and Drug Administration recently issued a public safety communication on acetaminophen, the active ingredient found in Tylenol and other over-the-counter pain reliever, linking the commonly-used painkiller ingredient to three rare, but serious skin reactions.
It should come as no surprise.
The first civil lawsuit against medical device maker C.R. Bard, manufacturer of the Avaulta Transvaginal Mesh, had been going on for little more than a week when it was revealed that the supplier of the plastic material used to manufacture the device had warned the company that their product – polypropylene – was unsuitable for use in the human body.
Several months ago, we brought you a story about a small-town, family-owned drug store in West Virginia (one of the last of its kind), that was dragged into Actos litigation by a plaintiff on grounds that the pharmacy's owner knew about the harmful effects of the medication and failed to inform the patient.
Dialysis drug GranuFlo has been linked to sudden cardiac arrest and death in patients. The drug is manufactured by German-based Fresenius Medical Care.
On November 4, 2011, Fresenius sent an internal memoto its dialysis centers warning that failure to account for excess bicarbonate resulting from an ingredient found in their product, GranuFlo, was associated with “6 to 8 fold greater risk of CP [cardiopulmonary] arrest and sudden cardiac death.
Followers of Ring of Fire radio probably noticed a disturbing report recently about Boehringer-Ingelheim's (BI) efforts to expand the use of its anticoagulant drug, Pradaxa (dabigatran) in Europe – despite the fact that the medication has been implicated in the deaths of more than five hundred patients.
In June, the government of India joined those of France and Germany in banning Takeda's flagship diabetic treatment, pioglitazone – better known as Actos, which as been strongly implicated in placing patients at an increased risk of developing bladder cancer. According to a media source in that country, the reason was “the [Indian] Health Ministry’s commitment to a parliamentary committee that it would immediately suspend medicines not allowed for sale in major international markets.”
SAN FRANCISCO July 23, 2013 - The Levin, Papantonio law firm is pleased to announce that two of its shareholders, Mark Proctor and Mike Papantonio, were presented today with the David S. Shrager President’s Award from the American Association for Justice (AAJ). The Award is considered the highest honor from the AAJ, the nation’s largest association of trial lawyers who work on behalf of the public, not corporations.
On Tuesday, July 16th, pharmaceutical giant Johnson & Johnson triumphantly reported that its earnings for the second quarter of 2013 were more than twice that of the same period last year. According to a New York Times article, these increased earnings were largely due to “strong sales of prescription drugs” and revenue from selling off one of its overseas assets in Ireland, as well as its diversified product line.